Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paroxetine Mesylate

FDA-approved product (tablet, oral), marketed as Paroxetine, Paroxetine Hydrochloride, Paxil and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Paroxetine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Major depressive disorder
  • Menopause
  • Obsessive-compulsive disorder
  • Panic disorder
  • Post-traumatic stress disorder
  • Social anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paroxetine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paroxetine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Electroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging Mechanisms

    NCT07392645 · start 2026-02-01

    Registered record
    Registry ID
    NCT07392645
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Electroacupuncture (EA); Sham Electroacupuncture (SEA); Routine Medication
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2027-12-31
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionElectroacupuncture (EA); Sham Electroacupuncture (SEA); Routine Medication
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Building Ukraine's Strength in PTSD Treatment and Research

    NCT07318181 · start 2026-01-01

    Registered record
    Registry ID
    NCT07318181
    Conditions
    Post Traumatic Stress Disorder; Post Traumatic Stress Disorder PTSD; Post-Traumatic Stress Disorder, PTSD
    Interventions
    Reconsolidation of Traumatic Memories Protocol; Trauma-Focused Cognitive Behavioral Therapy; Eye Movement Desensitization and Reprocessing; Selective Serotonin Reuptake Inhibitors: Paroxetine, Sertraline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-01-01
    Completion
    2028-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Stress Disorder; Post Traumatic Stress Disorder PTSD; Post-Traumatic Stress Disorder, PTSD
    InterventionReconsolidation of Traumatic Memories Protocol; Trauma-Focused Cognitive Behavioral Therapy; Eye Movement Desensitization and Reprocessing; Selective Serotonin Reuptake Inhibitors: Paroxetine, Sertraline
    PhaseNot applicable
    Registry statusRecruiting

  • Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

    NCT06232109 · start 2024-02-22

    Registered record
    Registry ID
    NCT06232109
    Conditions
    Drug Drug Interaction
    Interventions
    Fluvoxamine; Itraconazole; Paroxetine; ASN51
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-02-22
    Completion
    2024-07-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction
    InterventionFluvoxamine; Itraconazole; Paroxetine; ASN51
    PhasePhase 1
    Registry statusCompleted

  • A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

    NCT06049797 · start 2023-11-15

    Registered record
    Registry ID
    NCT06049797
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Paroxetine; Citalopram; Escitalopram; Desvenlafaxine; Venlafaxine; Gabapentin; Clonidine; Pregabalin; Oxybutynin; Any other SSRI/SNRI not already specified; Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-11-15
    Completion
    2026-05-07
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Paroxetine; Citalopram; Escitalopram +8 more
    PhaseNot recorded
    Registry statusCompleted

  • Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

    NCT05952713 · start 2022-10-01

    Registered record
    Registry ID
    NCT05952713
    Conditions
    Major Depressive Disorder
    Interventions
    Antidepressant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2023-07-01
    Enrolment
    73,336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionAntidepressant
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms

    NCT05637671 · start 2022-02-10

    Registered record
    Registry ID
    NCT05637671
    Conditions
    Vasomotor Symptoms
    Interventions
    oxybutynin ER; Paroxetine CR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-02-10
    Completion
    2023-12
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Symptoms
    Interventionoxybutynin ER; Paroxetine CR
    PhasePhase 3
    Registry statusUnknown

  • A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

    NCT04965272 · start 2021-08-18

    Registered record
    Registry ID
    NCT04965272
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Cariprazine 0.75 mg/day; Cariprazine 1.5 mg/day; Cariprazine 3.0 mg/day; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2021-08-18
    Completion
    2021-08-24
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionCariprazine 0.75 mg/day; Cariprazine 1.5 mg/day; Cariprazine 3.0 mg/day; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging （fMRI） Study With Paroxetine Treatment

    NCT03894085 · start 2019-05-30

    Registered record
    Registry ID
    NCT03894085
    Conditions
    Anxiety Disorder; Obsessive-Compulsive Disorder
    Interventions
    Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-05-30
    Completion
    2022-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorder; Obsessive-Compulsive Disorder
    InterventionParoxetine
    PhaseNot applicable
    Registry statusCompleted

  • Predicting Treatment Response in Patients With OCD

    NCT03993535 · start 2018-10-10

    Registered record
    Registry ID
    NCT03993535
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    selective serotonin reuptake inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-10-10
    Completion
    2023-04-30
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    Interventionselective serotonin reuptake inhibitor
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

    NCT02458690 · start 2015-07

    Registered record
    Registry ID
    NCT02458690
    Conditions
    Depression; Major Depressive Disorder; Dysthymic Disorder; Depressive Symptoms; Cardiovascular Diseases; Heart Diseases; Coronary Artery Disease; Stroke
    Interventions
    Beating the Blues (BtB); Problem Solving Treatment in Primary Care (PST-PC); Antidepressant Medications; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07
    Completion
    2021-03
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Major Depressive Disorder; Dysthymic Disorder; Depressive Symptoms +4 more
    InterventionBeating the Blues (BtB); Problem Solving Treatment in Primary Care (PST-PC); Antidepressant Medications; Usual Care
    PhasePhase 2
    Registry statusCompleted

  • Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis

    NCT02476136 · start 2015-05

    Registered record
    Registry ID
    NCT02476136
    Conditions
    Anxiety Disorders; Panic Disorder; Obsessive-compulsive Disorder; Post-traumatic Stress Disorder; Generalized Anxiety Disorder; Social Anxiety Disorder
    Interventions
    paroxetine, duloxetine, fluoxetine or venlafaxine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2016-12
    Enrolment
    8,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorders; Panic Disorder; Obsessive-compulsive Disorder; Post-traumatic Stress Disorder +2 more
    Interventionparoxetine, duloxetine, fluoxetine or venlafaxine
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

    NCT02022709 · start 2014-01

    Registered record
    Registry ID
    NCT02022709
    Conditions
    Obsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders
    Interventions
    Fluoxetine; Sertraline; Paroxetine; Citalopram; Fluvoxamine; Exposure and Response Prevention
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01
    Completion
    2018-03-13
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders
    InterventionFluoxetine; Sertraline; Paroxetine; Citalopram +2 more
    PhasePhase 4
    Registry statusCompleted

  • Alternatives for Reducing Chorea in Huntington Disease

    NCT01897896 · start 2013-11-12

    Registered record
    Registry ID
    NCT01897896
    Conditions
    Chorea Associated With Huntington Disease
    Interventions
    SD-809
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11-12
    Completion
    2017-08-21
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChorea Associated With Huntington Disease
    InterventionSD-809
    PhasePhase 3
    Registry statusCompleted

  • Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

    NCT01838681 · start 2013-06

    Registered record
    Registry ID
    NCT01838681
    Conditions
    Major Depressive Disorder
    Interventions
    Placebo; Brexpiprazole; ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-06
    Enrolment
    1,986

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPlacebo; Brexpiprazole; ADT
    PhasePhase 3
    Registry statusCompleted